Alteral Therapeutics ApS: Financial statements 2023
CVR: 43730967
Source: annual report 2023, Danish Business Authority
22/12/2022 – 31/12/2023
Alteral Therapeutics ApS (CVR 43730967) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK 294,398. Equity in the 2023 report amounted to DKK 334,398. The solvency ratio was 80.3%.
- Profit/Loss
- DKK 294,398
- Equity
- DKK 334,398
- Total Assets
- DKK 416,216
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 9, 2023, Allan Traugott Wehnert is registered as director of Alteral Therapeutics ApS.
As of October 9, 2023, Rasmus Christian Drewes Jensen has stepped down as director of Alteral Therapeutics ApS.
As of October 9, 2023, Wehnert Holding ApS is registered as an owner of Alteral Therapeutics ApS with an ownership share of 100%.
As of August 21, 2023, Allan Traugott Wehnert has stepped down as director of Alteral Therapeutics ApS.
About Alteral Therapeutics ApS
Alteral Therapeutics ApS is a Danish company of the type Anpartsselskab based in Allerød, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Allan Traugott Wehnert. The company is owned by Wehnert Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -125,267 and a net result of DKK 624,026 compared with DKK 20,137 the year before. Equity in the 2025 report amounted to DKK 978,560.